Technical Articles

Epithelial ovarian cancer (OvCa) is one of the most deadly malignant tumors in the female reproductive system. It is difficult to diagnose early, has a high recurrence rate, and has a low five-year survival rate, making it a difficult problem to be overcome in the field of oncology. In recent years, with the rapid development of molecular biology and immunotherapy, folate receptor 1 (FOLR1, also known as FRα) has gradually become a hot spot in the study of targeted therapy of ovarian cancer due to its specific expression in epithelial tumors.

FOLR1, also known as folate receptor alpha, is a glycoprotein widely expressed on the surface of human cells. It primarily facilitates the transport and metabolism of folate within cells, playing a critical role in cell growth and division. However, in various cancer cells, the expression level of FOLR1 is frequently aberrantly elevated, rendering it a potential therapeutic target for cancer treatment.